In an article in CURE, PC3I Faculty Emily Ko, MD, MSCR, discusses targeted therapy, a form of cancer treatment aimed at specific aspects of cancer cells which is an emerging treatment for endometrial cancer.
About 30% of patients with endometrial cancer have tumors that are MSI (microsatellite instability)-high, a characteristic linked to a high number of genetic mutations in cancerous cells. These abnormalities can be directly targeted with certain drugs.
“When we started to get down to the genomic levels of these tumors, we realized that just because some endometrial cancers may look [similar] under the microscope, they may still behave biologically different based on genomic signature,” says Ko. “Based on that genomic signature, there may be biologic pathways that we can target.”
Dr. Ko further discusses the potential of targeted therapies as an alternative treatment for endometrial cancer in the full article at CURE.
Reflecting on 50 years of the National Cancer Act, PC3I Faculty Ravi Parikh shares his thoughts with AARP on new cancer treatments and improvements in managing treatment side effects.
Dr. Christine Edmonds and PC3I Faculty Dr. Lola Fayanju share several ways in which Black women experience socioeconomic barriers and systemic biases that impact breast cancer treatment and survival.
Researchers from the Population-based Research to Optimize the Screening Process (PROSPR) Consortium are working to eliminate disparities in uptake of lung cancer screening.